About this episode

Darshan Kulkarni discusses the legal differences between branded and compounded drugs, emphasizing the importance of FDA approval.

Send us Fan Mail In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on t...

More episodes of DarshanTalks Podcast

• Why Private Membership Associations Fail FDA Scrutiny · April 16, 2026 · 7 min
• The Hidden Reason Sites are Firing Recruiters · April 11, 2026 · 8 min
• Don’t Let Your PI Walk Away With Your Study · April 10, 2026 · 1 min
• "Basically Employees" Isn't a Legal Category (And the OIG Knows It) · April 6, 2026 · 4 min
• The Hidden Legal Risks of AI Sponsor Protocols · April 3, 2026 · 1 min
• The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable · April 2, 2026 · 3 min

Explore listener stats, chart rankings, contacts and more on the DarshanTalks Podcast podcast page.